Molibresib
- Generic Name
- Molibresib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H22ClN5O2
- CAS Number
- 1260907-17-2
- Unique Ingredient Identifier
- 5QIO6SRZ2R
- Background
Molibresib is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies).
- Associated Conditions
- -
- Associated Therapies
- -
Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma
Phase 1
Withdrawn
- Conditions
- Unresectable NUT CarcinomaMetastatic NUT Carcinoma
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2020-09-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT04116359
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas
Phase 1
Withdrawn
- Conditions
- Advanced LymphomaAnn Arbor Stage III T-Cell Non-Hodgkin LymphomaAnn Arbor Stage IV T-Cell Non-Hodgkin LymphomaRefractory Malignant Solid NeoplasmAnn Arbor Stage III B-Cell Non-Hodgkin LymphomaAnn Arbor Stage IV B-Cell Non-Hodgkin LymphomaRefractory LymphomaRefractory T-Cell Non-Hodgkin LymphomaStage II Pancreatic Cancer AJCC v8Stage IIA Pancreatic Cancer AJCC v8
- Interventions
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2020-09-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT03925428
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath